Vaccine efficacies against EV71-associated hospitalization ( 0 cases vs. 24 cases ) and hand , foot , and mouth disease with neurologic complications ( 0 cases vs. 8 cases ) were both 100 % ( 95 % CI , 83.7 to 100 and 42.6 to 100 , respectively ) .